Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 32Breast Neoplasms 19Head and Neck Neoplasms 16Neoplasms 11Glioblastoma 8Adenocarcinoma of Lung 8Squamous Cell Carcinoma of Head and Neck 7Colorectal Neoplasms 7Brain Neoplasms 7Adenocarcinoma, Bronchiolo-Alveolar 7Prostatic Neoplasms 6Neoplasm Metastasis 6Gliosarcoma 6Rectal Neoplasms 5Ovarian Neoplasms 5Colonic Neoplasms 5Esophageal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Respiratory Tract Diseases 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrent Uterine Corpus Carcinoma × Gefitinib × Clear all
NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡